Arcus Biosciences Files 8-K
Ticker: RCUS · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1724521
Sentiment: neutral
Topics: corporate-action, sec-filing
TL;DR
Arcus Biosciences filed an 8-K on June 6th, covering shareholder votes and other company events.
AI Summary
Arcus Biosciences, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of security holders, other events, and financial statements and exhibits. The filing does not contain specific details about the matters voted upon or the nature of the other events.
Why It Matters
This filing indicates Arcus Biosciences is updating the SEC on corporate actions, which could include significant shareholder votes or other material events impacting the company.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that immediately suggests significant financial or operational risk.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- June 6, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of security holders?
The filing does not specify the exact matters submitted to a vote of security holders, only that this item is being reported.
What were the 'Other Events' reported in this 8-K?
The filing does not provide details on the specific 'Other Events' that are being reported.
Are there any new financial statements or exhibits included with this filing?
The filing indicates that 'Financial Statements and Exhibits' are part of the report, but the specific contents are not detailed in the provided text.
What is the principal executive office address for Arcus Biosciences?
The principal executive offices are located at 3928 Point Eden Way, Hayward, California 94545.
When is Arcus Biosciences' fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-06 16:28:54
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20240606.htm (8-K) — 39KB
- exhibit101-nonxemployeedir.htm (EX-10.1) — 16KB
- 0001724521-24-000101.txt ( ) — 179KB
- rcus-20240606.xsd (EX-101.SCH) — 2KB
- rcus-20240606_lab.xml (EX-101.LAB) — 21KB
- rcus-20240606_pre.xml (EX-101.PRE) — 12KB
- rcus-20240606_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 6, 2024, Arcus Biosciences, Inc. (the " Company ") held its annual meeting of stockholders. The results of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal 1 : The election of Class III directors to hold office until the 2027 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Kathryn Falberg 66,352,943 10,783,215 8,822,193 Linda Higgins 61,694,808 15,441,350 8,822,193 Terry Rosen 67,130,968 10,005,190 8,822,193 Proposal 2 : The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 84,330,586 1,242,487 385,278 Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 74,230,276 2,863,260 42,662 8,822,193
01 Other Events
Item 8.01 Other Events. On June 6, 2024, the Company's Board of Directors, upon the recommendation of the Compensation Committee, revised its Non-Employee Director Compensation Program. The Non-Employee Director Compensation Program, as so revised, is filed as Exhibit 10.1 to this Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Non-Employee Director Compensation Program 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: June 6, 2024 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)